A Study to Evaluate the Safety and Efficacy of Aprepitant (MK0869) for Chemotherapy-Induced Nausea and Vomiting in Pediatric Patients
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Aprepitant was approved in 2003. The drug works to lessen the amount of nausea and vomiting that cancer patients experience after treatment. Aprepitant has been well-studied in adults, but not in children. Data from adult studies has shown aprepitant to be safe. It has also been shown to be effective in lessening the amount of nausea and vomiting that adult patients experience. Because aprepitant has been shown to be safe and effective, the investigators have been using it in pediatric patients at this hospital as standard of care. The investigators will be surveying patients already receiving aprepitant for prevention of chemotherapy-induced nausea and vomiting to determine the amount of nausea and vomiting they experience. The investigators will also be surveying these patients to determine what their appetite is like and if they experience any disruptions in activities of daily living. The investigators are also going to be assessing any side effects these patients experience from receiving aprepitant.
Condition or disease
Chemotherapy-Induced Nausea and Vomiting
This will be a prospective, observational study conducted at WVU Children´s Hospital. The study will be conducted over a one—year period until data from 20—40 patient encounters is obtained. There will be no randomization and no control group. Information will be collected from all patients who meet the study´s inclusion criteria. Patients will be given a survey to complete at baseline, on all days of chemotherapy, and for five days after the conclusion of chemotherapy using the BARF Scale and a 4—point Likert scale. The information collected from the survey will include the incidence and severity of nausea and emesis, evaluation of appetite, activities of daily living, and rescue medications used for acute CINV. The specific chemotherapy regimen that each patient receives will be recorded. Any data identifying the patient will be de—identified after all pertinent data is collected. Descriptive statistics will be used to analyze data.
Number of episodes of nausea and vomiting [ Time Frame: Five days after end of chemotherapy ]
The primary outcome measure is assessing the incidence of chemotherapy-induced nausea and vomiting in pediatric patients receiving highly or moderately emetogenic chemotherapy and a prophylactic regimen that includes aprepitant. The incidence of chemotherapy-induced nausea and vomiting will be evaluated using the BARF Scale and a 4-point Likert scale on all days of chemotherapy and for five days following the conclusion of chemotherapy compared to baseline
Secondary Outcome Measures :
Appetite score on a 4-point Likert scale [ Time Frame: Five days after the end of chemotherapy ]
Patients will be assessed for changes in appetite using a 4-point Likert scale at baseline, on all days of chemotherapy, and for the five days following the conclusion of chemotherapy
Activities of daily living score on a 4-point Likert scale [ Time Frame: Five days after the end of chemotherapy ]
Patients will be assessed for changes in activities of daily living using a 4-point Likert scale at baseline, on all days of chemotherapy, and for five days following the conclusion of chemotherapy
Number of medications used for breakthrough nausea and vomiting [ Time Frame: Five days after the end of chemotherapy ]
The usage of all breakthrough medications for chemotherapy-induced nausea and vomiting while in the hospital will be recorded.
Participants with Adverse Events as a Measure of Safety and Tolerability [ Time Frame: Five days after the end of chemotherapy ]
Incidence of adverse events that can be definitely or probably related to aprepitant using the Naranjo Adverse Event Scale.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
1 Year to 17 Years (Child)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
This study will include pediatric patients with an active malignancy.
Patient is between the ages of 1-17 years
Patient has a confirmed malignancy
Patient is receiving highly or moderately emetogenic chemotherapy
Receiving aprepitant as part of an anti-emetic regimen
Patient's legally-authorized representative understands and voluntarily signs the written informed consent prior to any study-specific procedures. A copy of the signed informed consent form will be retained by the treating institution.
Patient ≥7 years of age understands and voluntarily signs the written informed assent form prior to any study specific procedures. A copy of the signed informed assent form will be retained by the treating institution.
Pregnant or breast feeding
Concomitant use of pimozide, terfenadine, astemizole, or cisapride